Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-25-004644
Filing Date
2025-06-09
Accepted
2025-06-09 16:40:01
Documents
1
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 4285
  Complete submission text file 0001562180-25-004644.txt   5763
Mailing Address C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153
Business Address
Mulligan Richard (Reporting) CIK: 0001376247 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39941 | Film No.: 251034671

Mailing Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102
Business Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102 (206) 701-7914
Sana Biotechnology, Inc. (Issuer) CIK: 0001770121 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)